METASTATIC MEDULLARY THYROID CANCER
Clinical trials for METASTATIC MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for METASTATIC MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can reprogrammed immune cells take on a rare thyroid cancer?
⭐️ CURE ⭐️ OngoingThis early-phase trial is testing whether a single infusion of specially engineered immune cells (called CAR T cells) can safely target and attack medullary thyroid cancer that has spread or come back. The cells are designed to recognize a protein called GFRα4 found on the cancer…
Matched conditions: METASTATIC MEDULLARY THYROID CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Targeted drug regorafenib tested in rare thyroid cancer
Disease control OngoingThis phase II study tests the targeted therapy regorafenib (Stivarga) in 8 people with metastatic medullary thyroid cancer that has progressed after prior treatment. The drug aims to block cancer growth by targeting specific proteins. Researchers are measuring how long participan…
Matched conditions: METASTATIC MEDULLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 26, 2026 16:10 UTC